Journal Publications

Expand All

2020


2019


Hay AE, Pater JL, Corn E, Han L, Camacho X, O’Callaghan C, Chong N, Bell EN, Tu D,
Earle CC. Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes. Clinical Trials 16: 14-7, 2019.


2018


- Ediebah DE, Quinten C, Coens C, Ringash J, Dancey J, Zikos E, Gotay C, Brundage M,


- Chia SK, Ellard SL, Mates M, Welch S, Mihalciou C, Miller WH, Gelmon K, Lohrisch C,


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

1027-37, 2017.


- Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.
Supportive Care in Cancer 24: 4871-8, 2016.


Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-


2014


- Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.


2013


- Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF,


2012


- Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-74, 2012.


2011


- Lyerly HK, Abernethy AP, Stockler MR, Koczwara B, Aziz Z, Nair R, Seymour L. Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers

- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrusis IL, Pritchard KI. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.
- Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, Trneny M, Shepherd L, Gill DS,


Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-6, 2011.


2010


• Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, Tu D, Parulekar WR. A phase 2 study of platinum and gemcitabine in patients with advanced salivary


- Pisters KMW, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery With or Without Preoperative Paclitaxel and


2009


• Bjarnason GA, MacKenzie RG, Nabid A, Hodson ID, El-Sayed SM, Grimard L, Brundage


2008


- Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K. Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. A


2007


Siu L, Soulières D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang


2006


- Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.


2005


- Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB


- Ouyang Y, Li D, Pater JL, Levine M. The importance of temporal effects in evaluating


2004


- Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumour studies of targeted,


2003


- Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the NCIC Clinical Trials


Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, MacIntosh LW, Geary RS, Eisenhauer EA. Phase II randomized study of ISIS 3521 and ISIS 5132 in...


2001


Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to


1999


- Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.


1998

- Levine M, Pritchard K, Bramwell V, Shepherd L. Adjuvant chemotherapy with CEF


- Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ. Phase I and pharmacological study of


1997


- Osoba D, Aaronson N, Zee B, te Velde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.
- Tu D. A comparative study of some statistical procedures in establishing therapeutic


1996

- Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.
- Osoba D, Dancey J, Zee B, Myles J, Pater J. Health-related quality-of-life studies of the


• Payne D, Coy P, Hodson I, Murray N, Pater J, Wilson K. Coy et al. original article (Patterns of failure following loco-regional radiotherapy in the treatment of limited stage...


1994


1993


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

301-8, 1993.


1992


1991

- Belch, A, Bergsagel, D, Wilson K, O'Reilly, S, Wilson J, Sutton D, Pater J, Johnston D,


1990


1989


1988


1987

• Quirt I, Eisenhauer E, Bramwell V, Knowling M, Grafton C, Hirte W, Cripps M, Maksymiuk A. Phase II study of mitroxnatron in untreated and previously minimally


1986

1985


1984

- Pater J, Willan A. Clinical trials as diagnostic tests. Controlled Clin Trials 5: 107-13,
1984.


1980


1979